RT Journal Article
SR Electronic
T1 A neutrophil activation signature predicts critical illness and mortality in COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.01.20183897
DO 10.1101/2020.09.01.20183897
A1 Matthew L. Meizlish
A1 Alexander B. Pine
A1 Jason D. Bishai
A1 George Goshua
A1 Emily R. Nadelmann
A1 Michael Simonov
A1 C-Hong Chang
A1 Hanming Zhang
A1 Marcus Shallow
A1 Parveen Bahel
A1 Kent Owusu
A1 Yu Yamamoto
A1 Tanima Arora
A1 Deepak S. Atri
A1 Amisha Patel
A1 Rana Gbyli
A1 Jennifer Kwan
A1 Christine H. Won
A1 Charles Dela Cruz
A1 Christina Price
A1 Jonathan Koff
A1 Brett A. King
A1 Henry M. Rinder
A1 F. Perry Wilson
A1 John Hwa
A1 Stephanie Halene
A1 William Damsky
A1 David van Dijk
A1 Alfred I. Lee
A1 Hyung J. Chun
YR 2020
UL http://medrxiv.org/content/early/2020/09/02/2020.09.01.20183897.abstract
AB Pathologic immune hyperactivation is emerging as a key feature of critical illness in COVID-19, but the mechanisms involved remain poorly understood. We carried out proteomic profiling of plasma from cross-sectional and longitudinal cohorts of hospitalized patients with COVID-19 and analyzed clinical data from our health system database of over 3,300 patients. Using a machine learning algorithm, we identified a prominent signature of neutrophil activation, including resistin, lipocalin-2, HGF, IL-8, and G-CSF, as the strongest predictors of critical illness. Neutrophil activation was present on the first day of hospitalization in patients who would only later require transfer to the intensive care unit, thus preceding the onset of critical illness and predicting increased mortality. In the health system database, early elevations in developing and mature neutrophil counts also predicted higher mortality rates. Altogether, we define an essential role for neutrophil activation in the pathogenesis of severe COVID-19 and identify molecular neutrophil markers that distinguish patients at risk of future clinical decompensation.Competing Interest StatementThe authors have declared no competing interest.Funding StatementSupported by a gift donation from Jack Levin to the Benign Hematology program at Yale, the National Institutes of Health (HL142818 to HJC, DK079310 and DK113191 to FPW, GM136651 and HL139116 to MLM), the American Heart Association (Transformational Project Award to HJC), and the DeLuca Center for Innovation in Hematology Research at Yale Cancer Center.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Yale University approved IRB #s:2000027792, 1401013259 and 2000028509All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesN/A